

In Silico Analysis of Transcriptomic Profiling and Affected Biological Pathways in Multiple Sclerosis

Rutvi Vaja^{1*}, Harpreet Kaur², Mohit Mazumder², Elia Brodsky²

¹Department of Biomedical Sciences and Research, School of Science, Navrachana University, Gujarat, India; ²Pine Biotech, New Orleans, Louisiana, USA

ABSTRACTs

Multiple Sclerosis (MS) is a chronic autoimmune, inflammatory neurological disease that is widely associated with Grey and white matter degradation due to the demyelination of axons. Thus exposing the underlying causes of this condition can lead to a novel treatment approach for Multiple Sclerosis. The total RNA microarray processed data from GEO for Multiple Sclerotic (MS) patients was comprehensively analyzed to find out underlying differences between Grey Matter Lesions (GML), Normal Appearing Grey Matter (NAGM), and Control Grey matter at the transcriptomics level. Thus, in the current study, we performed various bioinformatics analyses on transcriptional profiles of 184 samples including 105 NAGM, 37 GML, and 42 Controls obtained from the NCBI-Bio project (PRJNA543111). First, exploratory data analysis based on gene expression data using Principal Component Analysis (PCA) depicted distinct patterns between GML and CG samples. Subsequently, the Welch's T-test differential gene expression analysis identified 1525 significantly differentially expressed genes (p. adj value <0.05, Fold change (>= +/- 1.5) between these conditions. This study reveals the genes like *CREB3L2*, *KIF5B*, *WIP11*, *EP300*, *NDUFA1*, *ATG101*, and *TAF4* as the key features that may substantially contribute to loss of cognitive functions in Multiple Sclerosis and several other neurodegenerative disorders. Further, this study also proposes genes associated with Huntington's disease in multiple sclerotic patients. Eventually, the results presented here reveal new insights into MS and how it affects the development of male primary sexual characteristics.

Keywords: Multiple sclerosis; Huntington's disease; Myelinated axons; Grey matter

Abbreviations: MS: Multiple Sclerosis; GML: Grey Matter Lesions; CGM: Control Grey Matter; CG: Control Samples; NAMG: Normal Appearing Grey Matter; CNS: Central Nervous System; HD: Huntington's Disease; *WIP11*: WD Repeat Domain Phosphoinositide Interacting 1; CREB: cAMP Response Element-Binding Protein.

INTRODUCTION

As per the Multiple Sclerosis Association of America (MSAA), Multiple Sclerosis (MS) is an auto-immune, demyelinating disease that mainly affects the central nervous system. The main symptom of MS is the demyelination of axons. MS is the most common cause of neurological disability in young children. It is a long-term disease that affects the brain, spinal cord, and optic nerves [1-3]. There are 4 subtypes of MS which are categorized based on relapses, attacks, and exacerbations. The types of MS are namely: Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary-Progressive MS (SPMS), and Primary Progressive MS (PPMS). Among all these sub-types RRMS occurs in 80-85% of patients, which is the most common form and involves episodes of increasing symptoms followed by periods of remission. Over time then RRMS proliferates and progresses to SPMS and

PPMS stages of MS. As per the National MS Society, there are now 2.8 million people worldwide with reported cases of MS. MS are expressed differently in different phenotypes. MS and its subtypes have a highly diverse biological and clinical background for each patient depending upon the stage of MS showcased. MS has been originally regarded as an auto-immune disease affecting white matter. Recently histopathological studies have shown that MS also heavily affects the Grey matter and its cortical regions. Damage to grey matter starts at the early onset of the MS disease which further affects the cognitive functions of the brain [4-6]. The causes of grey matter damage are unclear, at the present.

Wells et al. [7] described Grey Matter Lesions (GML) as a symptom of MS in selected MS autopsy samples. The authors used conventional immunohistochemistry and detected a total of 1,595 lesions in 22 MS cases, of which 26% were located in the cortical GM or at the border of the WM and GM [8]. Grey matter lesions are classified

Correspondence to: Rutvi Vaja, Department of Biomedical Sciences and Research, School of Science, Navrachana University, Vadodara, India, E-mail: vajarutvi@gmail.com

Received: 16-May-2022, Manuscript No. IGOA-22-17563; **Editor assigned:** 20-May-2021, PreQC No. IGOA-22-17563 (PQ); **Reviewed:** 03-Jun-2022, QC No. IGOA-22-17563; **Revised:** 10-Jun-2022, Manuscript No. IGOA-22-17563 (R); **Published:** 17-Jun-2022, DOI: 10.35248/IGOA.22.7.167

Citation: Vaja R, Kaur H, Mazumder M, Brodsky E (2022) *In Silico* Analysis of Transcriptomic Profiling and Affected Biological Pathways in Multiple Sclerosis. Immunogenet Open Access.7:167.

Copyright: © 2022 Vaja R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

into 4 subtypes (Type 1, 2, 3, and 4) based on the location they develop on. Among the type 4 lesions occur in the cortex affecting all six layers [9, 10]. Lesions affecting the cortical areas of the brain are designated as either Type III or Type IV lesions [11-13]. Many of the recent post-mortem studies have shown that Grey matter lesions are found in the thalamus and Caudate nucleus. Other parts where GML occurs are namely putamen, pallidum, claustrum, amygdala, hypothalamus, and substantia nigra [14]. Early involvement of GML is found in all MS phenotypes and all MS subtypes as well. Both GM and lesions number and GML volume increase and progress over a given period. The number of GML in primary cortical areas of the brain directly affects the motor functions and causes motor dysfunction [14-17]. Overall GML is associated with cognitive impairments and cognitive dysfunction. Whereas GML about specific areas like cortical or hippocampal is associated with impaired visuospatial memory and processing speed [18-20].

The main goal of our study was to identify the underlying reasons at the transcriptomics level for Grey Matter degeneration in Multiple sclerosis which is originally a White matter degenerative disease. Our main concern was to investigate the affected biological pathways due to the formation of lesions in Grey Matter after diagnosis of Multiple sclerosis. We wanted to find out defects at the transcriptional level to better understand the proliferation, formation, and progression of lesions in the Grey Matter. As the GML expression is tissue-specific depending upon the phenotypes in which they occur, finding the underlying genes that cause lesions, Cognitive function loss and inflammation in MS could be very helpful for future treatments. It is to be noted that, patients with MS lesions showed larger cognitive disabilities than normal MS patients without lesions [21].

Hence, in the present study, we investigated transcriptomics profiles of Normal appearing grey matter (NAGM) and Grey Matter Lesions (GML) and healthy Control Samples (CG) to understand the affected Biological Pathways and genes behind the appearance of GML using various bioinformatics techniques. After identifying the significant genes between these groups; we scrutinized the affected biological pathways as the disease progresses to Normal Appearing Grey Matter (NAGM) and Grey Matter Lesions (GML) samples.

METHODOLOGY

Data sets

In this study, processed microarray data was taken from the NCBI GEO [GSE131282] The dataset of this project was generated by Geier et al. [22] and published as a bio project on NCBI with accession number PRJNA543111. This was our discovery data set. Transcriptome data contains microarray processed quantile normalized values using the Bioconductor package Lumi (version 2.32.0) of total RNA extracted from grey matter tissue from the Illumina HumanHT-12 V4.0 expression bead chip platform. The data set of the following Bio project is shown in Table 1 below. The validation dataset of this project was generated by Geier et al. [23] and published as a bio project on NCBI with accession number PRJNA543111. The GEO Accession number was GSE131279. Transcriptome microarray data contain quantile normalized values of RNA expression extracted from grey matter tissue using the Illumina HumanHT-12 V4.0 expression bead chip platform. This data set had the following number of samples shown in Table 1

below.

Table 1: Datasets used in the study.

Discovery data (Main dataset)		Validation dataset	
Disease state	Number of samples	Disease state	Number of samples
Normal appearing grey matter	105	Normal appearing grey matter	64
Grey matter lesions	37	Control samples	42
Control grey matter (Healthy)	42		

Data pre-processing

The microarray processed data was quintile normalized signal data. The processed data had Illumina probe ids. We mapped probe IDs with the gene symbols using the soft family files.

Exploratory analysis

Exploratory analysis facilitated the examination of variation between all samples, including healthy and diseased patients' samples (Normal appearing grey matter and Grey matter lesions). To understand the patterns in the data exploratory data analysis was performed using the Principal component analysis module integrated on the T-bio info server. PCA is a dimensionality reduction technique that discerns the variability between the samples. PCA was performed in four independent conditions: (1) All 3 conditions (Grey matter lesions Vs Normal appearing Grey Matter Vs Healthy Control Samples); (2) Grey matter lesions Vs Normal appearing Grey Matter; (3) Grey matter lesions Vs Control Grey Matter; and (4) Normal appearing Grey matter Vs Control Grey Matter. Eventually, the PCA scatter plots were used to determine the patterns (Figure 1).




Figure 1: Production and activities of IGF-1 and BDNF in the muscle and the brain by exercise.

Differential gene expression analysis

Differential Gene Expression (DGE) analysis was conducted by contrasting Grey matter lesions with Control grey matter samples. The Differential Gene Expression (DGE) analysis was performed using the Welch's T-test. Welch's T-test is a modification of statistical analysis used for getting statistical significance for unequal variances. When two groups have unequal sample sizes and variances-a Welch's Test can be applied [24]. The Welch's Test uses a one-step approach for DGE analysis and combines several

methods. The significant genes were identified with the threshold of (p.adj value <0.05, Fold change (>=± 1.5) (39).

Assessment of discriminatory potential of significant genes

Next, to assess and visualize the potential of significant genes in distinguishing both the classes of samples PCA and H-Clustering were performed with the selected set of significant RNA genes only. H-clustering (Distance: Euclidean, Linkage: average) was performed to understand the discriminatory potential of significant genes in distinguishing the GML and Control samples based on their gene expression. Eventually, heat maps were drawn to visualize the gene expression patterns among different classes of samples.

Gene enrichment analysis

To delineate the biological implication of the significant genes, the gene enrichment analysis for Gene Ontology (GO) terms was performed using the annotation module integrated on the T-bio info server. Further, significantly (p.adj value <0.05, Fold change (>=± 1.5) enriched KEGG pathways were identified using the Enrichr [25]. Enrichr is an easy-to-use intuitive enrichment analysis web-based tool providing various types of visualization summaries of collective functions of gene lists. Notably, enriched pathways and GO terms were also identified using the Enrichr Platform for significant up-regulated and down-regulated genes. Further, the Enrichr was also used to identify the associated gene ontology terms and biological pathways with significant up-regulated and down-regulated genes.

RESULTS

In the current study, we explored transcriptomics data of Normal Appearing Grey Matter (NAGM), Grey Matter Lesions (GML), and healthy control samples using various *in silico* techniques to delineate the underlying gene signature and biological pathways. The complete workflow of the study is represented below in Figure 2.




Figure 2: Work flow of the study representing the key steps.

Exploratory data analysis

Data were explored by using Principal Component Analysis (PCA). We did PCA to understand the variation between the 3 groups, namely Normal appearing Grey Matter, Grey Matter lesions, and Controls. Figure 3 shows the variation between GML and NAGM. The PC1 is 84.53% along with PC2 as 11.54% and PC3=0.60%. It is evident from the PCA of this exploratory analysis that there is something that triggers the variation between GML and NAGM.

Notably, variation between NAGM and Control samples is very diverse where PC1 as 81.94%, PC2 as 14.09% and PC3=0.70% as shown in Figure 4. Figure 5 represents variation between Control Grey Matter and Grey Matter lesion samples. The variation between 3 PCAs is given as PC1=69.69%, PC2=27.31% and PC3=0.54%. Further, NAGM and CG are not separating from each other based on PCA results, here PC, PC2 and PC3 represent 82.39%, 13.74% and 0.48% variation of the data, respectively as shown in Figure 6. Since the main focus of our study was to find out the underlying reason for Grey matter lesions and their degeneration, we decided to go with the Variance between GML and CG to further our analysis.




Figure 3: PCA for All 3 conditions: Grey Matter Lesions vs Normal Appearing Grey Matter vs Healthy Control Samples. Note: (●) Grey Matter Lesions; (●) Normal Appearing Grey Matter; (●) Control Grey Matter.




Figure 4: PCA for Grey Matter Lesions vs Normal Appearing Grey Matter. Note: (●) Grey Matter Lesions; (●) Normal Appearing Grey Matter.




Figure 5: PCA showing variance among control grey matter (healthy control) and grey matter lesion. Note: (●) Control Grey Matter; (●) Grey Matter Lesions.




Figure 6: PCA for normal appearing grey matter vs control grey matter samples. Note: (●) Normal Appearing Grey Matter; (●) Control Grey Matter.

Downstream analysis

It is evident from the PCA results (Figures 3-6) that the variation between Grey Matter lesions and Control grey matter samples is maximum. Hence, we further carried out a Comparative analysis between Grey matter lesions and healthy control samples. Based on Figure 5, it can be seen that healthy control samples and the Grey matter lesion samples are well separated, which means there is significant variation between these groups. Hence, in downstream analysis, we performed differential gene expression analysis between Grey Matter Lesions and healthy control samples. When the Grey Matter Lesion samples and control samples were examined in a specific scatter plot, it was obvious that there was an improvement in principal components, and the two groups were separated from each other. After the observed variation between the two groups-Grey Matter Lesions and Control Samples, the reason for this difference and its impacts could be investigated at the level of gene regulation.

Differential genes expression analysis

The differential gene expression analysis between the Grey Matter Lesions (GML) and Control Grey Matter (CGM) samples scrutinized 1525 significantly (p.adj value <0.05, Fold change $\geq \pm 1.5$). Among them, 438 genes were found to be significantly up regulated (p.adj value <0.05, Fold change $\geq +1.5$) genes and 1087 genes were found to be significantly down regulated (p.adj value <0.05, Fold change ≤ -1.5) in GML in comparison to CGM.

Clustering and heat map revealed variations among grey matter lesions and control samples

Hierarchical Clustering [26] was performed to understand whether significant genes are capable to form distinct clusters of Grey Matter lesions and Control Grey Matter samples based on their gene expression. Clustering results clearly show the distinct clusters of Grey Matter lesions and Control Grey Matter samples as shown in Figure 7. Heat map representing the expression pattern of significant genes among Grey Matter lesions and Control Grey Matter samples as shown in Figure 8.

Pathways involved in the pathogenesis of multiple sclerosis

To understand the biological importance of pathways, gene ontology analysis was performed. Interestingly, although there were different pathways in upregulated genes, many represented

biological pathways involved Huntington’s Disease, GTP binding biological processes, Mitochondrial Chain 1 respiratory complexes (Figure 9).




Figure 7: Hierarchical clustering results as dendrograms. Red boxes clusters indicate the control (healthy) samples, and the blue one represents the clusters of the GML (lesions) samples.




Figure 8: Heat-map representing the gene expression patterns of significantly differentially expressed genes.




Figure 9: Gene ontology and KEGG pathway analysis of up-regulated genes.

The same concept could be detected with down-regulated genes as shown in Figure 10. The gene ontology analysis for down-regulated pathways involved olfactory transduction pathways, Plasma membrane functional pathways, and the development of male primary sexual characteristics and gonad developmental pathways. According to the first principal component, Grey matter lesion had a lot of variability within its group. Per the experiments conducted by Subbiah-Pugazhenthii [27], it shows that cyclic AMP response element-binding protein (CREB) is a nuclear

transcription factor that plays a major role in neurodegenerative diseases and its progression. Also, CREB is responsible for the retention of memory and survival of neurons [28]. The role of the *TAF4* gene is increasing in neurodegeneration [29]. Hence after a literature review on the close association of Huntington's Disease (HD) associated genes involved/found in MS patients, we concluded. From our list of significantly expressed genes, many of the HD-associated genes were expressed differentially, specifically up-regulated. 7 HD-associated pathway genes that are significantly differentially expressed (up-regulated) in GML samples with their annotations are enlisted in Table 2.




Table 2: Differentially expressed 7 huntington disease-associated genes identified in our study.

Sr. No.	Illumina probe Id	Gene symbol	Gene description	P. adjusted value
1	ILMN_1751097	CREB3L2	cAMP responsive element binding protein 3 like 2	3.47E-53
2	ILMN_1788160	KIF5B	kinesin family member 5B	6.03E-48
3	ILMN_1781386	WIP1	WD repeat domain, phosphoinositide interacting 1	1.28E-55
4	ILMN_1744665	EP300	E1A binding protein p300	2.75E-74
5	ILMN_1784286	NDUFA1	NADH: Ubiquinone oxidoreductase subunit A1	6.32E-67
6	ILMN_1772527	ATG101	autophagy related 101	2.71E-52
7	ILMN_1737535	TAF4	TATA-box binding protein associated factor 4	1.15E-57

P. Adjusted value <0.05; Fold change(>=± 1.5)

In the heat map (Figure S1) that the majority of Huntington's associated genes are up-regulated in patients with multiple sclerosis lesions in comparison to the control samples. This was evident even in KEGG analysis (Figure 6A) as the Huntington Disease-associated pathway is significantly up-regulated in Grey Matter Lesions (MS).

Validation of the results

Next, to assess and validate the 7 Huntington's disease-associated genes expression patterns, we analyze the expression pattern of those 7 Huntington's disease-associated genes in a validation dataset containing patients of MS without lesions. It is evident from the Heat-map (Figure S1) that the 7 Huntington's disease-associated genes in Multiple sclerosis normal-appearing Grey Matter are highly up regulated in comparison to control samples in the discovery dataset. Hence, we also analyze the expression pattern of these genes in the validation data; the bar-plot (Figure S2) between Healthy (controls) and Normal appearing Grey matter without lesions (Multiple sclerosis) represents the expression pattern of the genes. Our validation results confirm our hypothesis. In the PCA plot (Figure S3), we can clearly see the distinct clusters. Similarly, hierarchical clustering results (Figure S4) confirming that the two groups form distinct clusters separately in the dendrogram, which implies these significant genes might predict MS characteristics [29].

DISCUSSION

The origin of lesions in Multiple Sclerotic patients remains unknown. Previous studies addressing this question have shown contrasting results, thus making it difficult to establish any one of the theories as to the answer [30]. In this study, we have attempted to reveal the close association of Multiple Sclerosis with several affected biological pathways namely Huntington disease-associated pathways using RNA-Seq Analysis. To identify differences in gene expression between Grey Matter Lesion samples and Healthy control samples, RNA-Seq analysis was performed on RNA-seq samples obtained from both of the samples. Exploratory data analysis using PCA revealed that the samples of both categories form separate clusters, depicting the vast genetic differences between the MS Grey matter lesions and Control samples. This hints towards the theory that there is something that triggers the progression of MS diseases which leads to the formation of lesions at the transcriptomics level. Further studies on the same would be able to divulge the series of events that take place during this transformation.

Based on differential gene expression analysis using Welch's T-Test, we observed 438 genes were significantly (adjusted P-value <0.05, Fold change ($\geq \pm 1.5$) up regulated and 1087 (adjusted P-value <0.05, Fold change ($\geq \pm 1.5$) genes were down regulated in GML in comparison to CGM. Next, the PCA plot and dendrogram from Hierarchical clustering indicated their significance in distinguishing GML and CGM. A heat map generated from these genes showed that most of the genes were down regulated in GML samples whereas some of them were up-regulated in GML samples, highlighting differential expression in both populations.

Gene ontology analysis performed using Enrich based on significant gene sets showed obvious involvement of genes, specifically in Grey matter degeneration, *via* functional annotation and clustering. However, hits were obtained for genes associated with cell adhesion, Huntington's Disease, Mitochondrial respiratory chain complexes, GTP-Protein synthesis, Olfactory and recovery adaptation pathways, migration, and invasion, indicating that their possible deregulation may have led to the formation of Grey Matter lesions. Further, pathway analysis demonstrated a better understanding of the involvement of the gene sets in pathways representing the Odour dysfunction in MS patients which is based on down regulation of olfactory transduction pathways. It also shows the up-regulation of pathways like Huntington disease-associated pathways, mitochondrial respiratory chain complex pathways, and GTP Protein binding pathways. This study shows that as per our KEGG Analysis pathways, the most affected pathway is the HD-associated pathway. The associated genes with this pathway are *CREB3L2*, *KIF5B*, *WIP11*, *EP300*, *NDUFA1*, *ATG101*, and *TAF4* [as per Enrichr] as the key features that may substantially contribute to loss of cognitive functions in neurodegenerative disorders like Multiple sclerosis, Huntington's disease, and further on. However, since our study was focused on samples of patients with multiple sclerosis, the involvement of certain genes that are also associated with HD is something of great importance. Studies have shown that the CREB Factor plays a major role in memory formation and neuronal regeneration [31]. The gene *TAF4* plays a significant role in controlling the differentiation of human neural progenitor cells [32]. Since *TAF4* is up-regulated in MS patients, in this study we have drawn a possible association between *TAF4* and neuronal degradation [33]. *TAF4* is primarily concerned with the production of human neural progenitor cells. However, from

our results depicted here, due to the significant up-regulation of *TAF4*, the production of new neural cells especially glial cells and neurons is hindered-leading to progressive neuroinflammation and neurodegeneration. Our results also depict severe up-regulation of the CREB gene which might be the possible causes of progressive neuronal degeneration and loss of cognitive functions in patients of MS [34]. The indication of such genes up-regulated in MS patients could be used as a predictive tool for identification that MS is progressing and this progression might be fatal and lead to severe other neurodegenerative disorders. Talking about the *KIF5B* gene, it is a motor neuron protein that plays a significant role in dendritic transport, synaptic plasticity, and memory retention [35]. *WIP11* (WD Repeat Domain, Phosphoinositide Interacting 1) is a protein-coding gene responsible for neuro degeneration because of its involvement in brain iron accumulation. Enhanced iron uptake in acute cases of MS has been reported which shows that the *WIP11* gene can play a leading cause in iron accumulation and neuro degeneration of the brain [36].

It should be also noted *WIP11*, *TAF4*, and *CREB* protein-coding genes are the ones that are also associated with the early onset of Huntington's disease [37]. Several studies have suggested that impairments of the autophagy process are associated with several neurodegenerative diseases like HD and MS (38). The depiction of these in patients of GML suggests that they are early predictive biomarkers for HD. Thus, while assessing the patients with MS, the Up-regulation of these genes can be used as a tool for recognizing progressive fatal neuro-degeneration and onset of HD [38].

However, it should be noted that in this study we have portrayed 7 genes (*CREB3L2*, *KIF5B*, *WIP11*, *EP300*, *NDUFA1*, *ATG101*, and *TAF4*) as the key features that may substantially contribute to loss of cognitive functions and progressive neuro degeneration involved in the MS pathogenesis. This study was able to identify several protein-coding genes whose role in the association with HD remains largely unclear [39]. Studying their functionality in the future may reveal key biomarkers or drug targets that could be exploited for MS in association with HD. People suffering from MS who might be potentially screened for HD can be looked upon for these genes in order to get signals for early onset of HD.

CONCLUSION

This study revealed significant differences in gene expression between Grey Matter Lesions and Healthy Control Samples. Importantly, we confirm and validate the significant up regulation of 7 HD pathway-associated genes in GML in comparison to normal samples. This most likely reveals an important clue to the etiology of this fatal neurodegenerative disease.

FUTURE DIRECTIONS

In the future, intensive research is required to assess the precise effect of Multiple sclerosis on genes like *NDUFA1*, *EP300*, and *ATG101*. More comprehensive research is needed to support these findings stated above. As part of a future study, it would be interesting to understand the changes in MS pathogenesis and its effects on olfactory transduction, Development of Primary male sexual characteristics, GTP Binding protein, and Plasma Membrane component pathways.

ACKNOWLEDGMENTS

This research was performed within the framework of the Research fellowship program and was supported by Pine Biotech. Data

processing and visualization pipelines were run with the T-Bio info Server.

ETHICS DECLARATIONS

Competing interests

The authors declare no competing financial and non-financial interests.

AUTHOR CONTRIBUTIONS

Rutvi Vaja proposed the research idea, performed the data analysis, and produced the figures and manuscript. Dr. Harpreet Kaur reviewed the data, provided assistance with analysis and interpretation, and supervised the whole project. Elia Brodsky and Dr. Mohit Mazumder provided expert reviews of the project.

REFERENCES

1. Le Grand M. The African American experience and multiple sclerosis. *Int J MS Care*. 2020; 22(2): 50-51.
2. Shulman KI, Feinstein A. Quick cognitive screening for clinicians: Clock-drawing and other brief Tests. CRC Press; 2003.
3. Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy. *Cell J* 2017; 19(1):1-5.
4. Vaja RD, Kaur H, Mazumder M, Brodsky E. In silico analysis of transcriptomic profiling and affected biological pathways in multiple sclerosis. *bioRxiv*. 2021 1.
5. Ontaneda D, LaRocca N, Coetzee T, Rudick RA. Revisiting the multiple sclerosis functional composite: proceedings from the national multiple sclerosis society (NMSS) task force on clinical disability measures. *Mult Scler J* 2012; 18(8):1074-1080.
6. Geurts JJ, Barkhof F. Grey matter pathology in multiple sclerosis. *Lancet Neurol*. 2008; 7(9):841-851.
7. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 1962; 25(4):315-317.
8. Roel Klaver. *Prion* 2013; 7(1): 66-75.
9. Kutzelnigg A, Lucchinetti CF, Stadelmann C, Ck W, Rauschka H, Bergmann M. Cortical demyelination and diffuse white matter injury in multiple sclerosis. *Brain*. 2005; 128(11):2705-2712.
10. Bø L, Vedeler CA, Nyland H, Trapp BD, Mørk SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. *Mult Scler J*. 2003; 9(4):323-331.
11. Geurts JJ, Bö L, Roosendaal SD, Hazes T, Daniëls R, Barkhof F, Witter MP, et al. Extensive hippocampal demyelination in multiple sclerosis. *J Neuropathol Exp Neurol*. 2007; 66(9):819-827.
12. Huitinga I, Groot CJ, Valk PV, Kamphorst W, Tilders FJ, Swaab DF. Hypothalamic lesions in multiple sclerosis. *J Neuropathol Exp Neurol*. 2001; 60(12):1208-1218.
13. Papadopoulos D, Dukes S, Patel R, Nicholas R, Vora A, Reynolds R. Substantial archaic cortical atrophy and neuronal loss in multiple sclerosis. *Brain Pathol*. 2009; 19(2):238-253.
14. Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, Mattioda A, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. *J Neuropathol Exp Neurol*. 2009; 68(5):489-502.
15. Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. *Arch Neurol*. 2007; 64(10):1416-1422.
16. Calabrese M, Rocca MA, Atzori M, Mattisi I, Favaretto A, Perini P, et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. *Ann Neurol*. 2010; 67(3):376-383.
17. Adad JC, Benner T, Greve D, Kinkel RP, Radding A, Fischl B, et al. In vivo evidence of disseminated subpial T2* signal changes in multiple sclerosis at 7 T: A surface-based analysis. *Neuroimage*. 2011; 57(1):55-62. (2011).
18. Calabrese M, Agosta F, Rinaldi F, Mattis I, Grossi P, Favaretto A, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. *Arch Neurol*. 2009; 66(9):1144-1150.
19. Roosendaal SD, Moraal B, Pouwels PJ, Vrenken H, Castelijns JA, Barkhof F, et al. Accumulation of cortical lesions in MS: Relation with cognitive impairment. *Mult Scler*. 2009; 15(6):708-714.
20. Roosendaal SD, Moraal B, Vrenken H, Castelijns JA, Pouwels PJW, Barkhof F, et al. In vivo MR imaging of hippocampal lesions in multiple sclerosis. *J Magn Reson Imaging*. 2008; 27(4):726-31.
21. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. *Neurol*. 2009; 67(6):960-967.
22. J. Lever, M. Krzywinski, N. Altman, points of significance: Principal component analysis. *Nat Methods*. 2017; 14(7), 641-642.
23. Fu Q, Hoijtink H, Moerbeek M. Sample-size determination for the Bayesian t test and Welch's test using the approximate adjusted fractional Bayes factor. *Behav Res Methods*. 2021; 53(1):139-152.
24. Vogt WP. *Dictionary of Statistics & Methodology: A Nontechnical Guide for the Social Sciences*. SAGE. Zimmerman, D. W. A note on preliminary tests of equality of variances. *Br J Math Stat Psychol*. 2004; 57(7): 173-181.
25. Chen EY, Tan CM., Kou Y. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinform*. 2013; 14(4), 128-130.
26. Kavuri VC, Liu H. Hierarchical clustering method to improve transrectal ultrasound-guided diffuse optical tomography for prostate cancer imaging. *Acad Radiol*. 2014; 21(2):250-262.
27. Pugazhenti S, Wang M, Pham S. Downregulation of CREB expression in Alzheimer's brain and in Aβ-treated rat hippocampal neurons. *Mol Neurodegener* 2011; 16 (6):60-62.
28. Mantamadiotis T, Lemberger T, Bleckmann SC, Kern H, Kretz O, Villalba AM, et al. Disruption of CREB function in brain leads to neurodegeneration. *Nat Genet*. 2002; 31(1):47-54.
29. Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch SM, et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. *Sci*. 2002; 96(5576):2238-2243.
30. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. *Clin Exp Immunol*. 162 (1):1-11. (2010)
31. Carlezon WA, Duman RS, Nestler EJ. The many faces of CREB. *Trends Neurosci*. 2005; 28(8):436-445.
32. Kazantseva J, Tints K, Neuman T, Palm K. TAF4 controls differentiation of human neural progenitor cells through hTAF4-TAFH activity. *J Mol Neurosci*. 2015; 55(1):160-166.
33. Bartesaghi S, Salomoni P. Tumor suppressive pathways in the control of neurogenesis. *Cell Mol Life Sci*. 2013; 70(4):581-597.
34. Zhao J, Fok AHK, Fan R, Kwan PY, Chan HL, Lo LH, et al. Specific depletion of the motor protein KIF5B leads to deficits in dendritic transport, synaptic plasticity and memory. *Elife*. 2020; 21(9) 53-56.
35. Williams R, Buchheit CL, Berman NE, LeVine SM. Pathogenic implications of iron accumulation in multiple sclerosis *J Neurochem*. 2012; 120(1):7-25.

36. Khalil M, Langkammer C, Ropele S, Petrovic K, Blazek MW, Loitfelder M, et al. Determinants of brain iron in multiple sclerosis: A quantitative 3T MRI study. *Neurology*. 2011; 77(18):1691-1697.
37. Kiriya Y, Nochi H. The function of autophagy in neurodegenerative diseases. *Int J Mol Sci*. 2015; 16(11):26797-26812.
38. Musharraf Jelani, Hannah Dooley, Andrea Gubas, Mohamoud HSA, Khan MTM, Zahir Ali, et al. A mutation in the major autophagy gene, WIPI2, associated with global developmental abnormalities. *Brain*. 2019; 142(5) 1242–1254,
39. Dalman MR., Deeter A, Nimishakavi G. Fold change and p-value cutoffs significantly alter microarray interpretations. *BMC Bioinform*. 2012; 13(2):11-13.